{"id":29567,"date":"2019-03-17T13:05:56","date_gmt":"2019-03-17T18:05:56","guid":{"rendered":"https:\/\/www.heart-valve-surgery.com\/heart-surgery-blog\/?p=29567"},"modified":"2019-08-21T18:05:59","modified_gmt":"2019-08-21T23:05:59","slug":"low-risk-tavr-clinical-trial-results","status":"publish","type":"post","link":"https:\/\/www.heart-valve-surgery.com\/heart-surgery-blog\/2019\/03\/17\/low-risk-tavr-clinical-trial-results\/","title":{"rendered":"Low-Risk TAVR Clinical Trial Results Released"},"content":{"rendered":"

Finally!\u00a0 We have results for one of the most talked about heart valve clinical trials at HeartValveSurgery.com!<\/p>\n

On Friday, at the American College of Cardiology (ACC)<\/a> conference in New Orleans, the results for the low-risk, transcatheter aortic valve replacement (TAVR) were released.<\/p>\n

As for the results… Drum roll please…<\/p>\n

 <\/p>\n

\"\"<\/p>\n

 <\/p>\n

<\/p>\n

The results of this clinical trial, known as the PARTNER 3 research study, were quickly applauded, cheered and celebrated!<\/p>\n

In fact, words like “game changer” have been used to describe the success of the clinical trial which investigated the use of the SAPIEN 3 device, a non-invasive treatment of aortic stenosis, in low-risk patients.\u00a0 Aortic stenosis<\/a> is an often mis-diagnosed and under-treated form of heart disease that can be fatal.<\/p>\n

 <\/p>\n

Data Compares Low-Risk TAVR to Surgical Aortic Valve Replacement<\/h2>\n

Similar to other clinical trials, the PARTNER 3 research study evaluated the outcomes of the current standard of care – surgical aortic valve replacement (SAVR) – to TAVR.\u00a0 As you may know, TAVR is a percutaneous and minimally-invasive method for replacing a stenotic aortic valve (i) without an incision the patient’s chest or ribs and (ii) without the use of the heart-lung machine.\u00a0 You can learn more about TAVR here<\/a>.<\/p>\n

Although TAVR was previously approved by the Food & Drug Administration (FDA) in the United States for inoperable, high-risk and intermediate risk patients, the use of TAVR for low-risk patients was the sole focus of the PARTNER 3 study sponsored by Edwards Lifesciences.<\/p>\n

When comparing TAVR to SAVR in this low risk trial, here select data that Dr. Marty Leon and Dr. Michael Mack<\/a>, the national principal investigators of PARTNER 3, revealed at the ACC for the 1,000 patient study:<\/p>\n